GlobeStar Therapeutics Corporation
GSTC
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 804.70K | 1.89M | 1.87M | 1.86M | 1.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 804.70K | 1.89M | 1.87M | 1.86M | 1.88M |
| Operating Income | -804.70K | -1.89M | -1.87M | -1.86M | -1.88M |
| Income Before Tax | -887.10K | -1.97M | -1.95M | -1.95M | -1.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.89 | -1.97 | -1.95 | -1.95 | -1.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -887.10K | -1.97M | -1.95M | -1.95M | -1.91M |
| EBIT | -804.70K | -1.89M | -1.87M | -1.86M | -1.88M |
| EBITDA | -- | -- | -- | -- | -299.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 4.28B | 3.91B | 3.56B | 3.31B | 3.08B |
| Average Diluted Shares Outstanding | 4.28B | 3.91B | 3.56B | 3.31B | 3.08B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |